India’s pharma exports surpass $30 billion in FY25, US top market
In a significant achievement, the pharmaceutical exports from India crossed $30 billion in the last financial year (FY25)
- NEW DELHI — In a significant achievement, the pharmaceutical exports from
India crossed $30 billion in the last financial year (FY25), with the US
remaining as a key market with more than one-third of the country's pharma
exports.
-
- According to official trade data, the pharmaceutical
exports reached $30,467.32 million in FY25, more than 9 per cent increase than
$27,851.70 million in FY24.
-
- In the month of March, the pharma exports registered more
than 30 per cent surge (year-on-year) to $3,681.51 million, from $2,805.71
million in the same month last fiscal, according to data.
-
- The exports to the US (in value terms) increased 14.29
per cent at $8,953.37 million in FY25. Other countries on top of India's pharma
exports were the UK, Brazil, France and South Africa last fiscal.
-
- Meanwhile, a report said last month that domestic
pharmaceuticals market is expected to grow 8-9 per cent year-on-year in FY26.
The report by India Ratings and Research (Ind-Ra) said the growth in the sector
will be at 7.5-8.0 per cent year on year for FY25.
-
- This is “against 6.5 per cent year-on-year in FY24 and
9.9 per cent YoY growth in FY23,” said Krishnanath Munde, associate director at
India Ratings and Research.
-
- In February, the pharma market delivered revenue of 7.5
per cent year on year. This growth was driven by growth in price (5.2 per cent
YoY) and new launches (2.4 per cent YoY), while volume growth continued to
remain muted at negative 0.2 per cent YoY, the report said.
-
- The sector reported growth at an average of 7.3 per cent
year-to-date (YTD) in FY25. This was led by price growth (5.5 per cent), new
launches growth (2.7 per cent), and volume growth.
-
- The pharma sector in the country is witnessing rapid production
growth. The Indian pharma sector has grown at 8 per cent CAGR and has also seen
a 9 per cent increase in export rates in 2024, according to a report by
McKinsey & Company.
-
